(Bloomberg) — Amgen Inc. will pay $13.4 billion for a blockbuster psoriasis drug from Celgene Corp., which is shedding the asset in order to win antitrust regulators’ sign-off for its $74 billion merger with Bristol-Myers Squibb Co.The all-cash deal will give Amgen a growing product at a time when the
https://finance.yahoo.com/news/amgen-buy-celgene-drug-13-145728408.html
Fox News
This site is not involved in the creation of this post.
